A Phase i Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C

Autor: Lu, NT, Crespi, CM, Liu, NM, Vu, JQ, Ahmadieh, Y, Wu, S, Lin, S, McClune, A, Durazo, F, Saab, S, Han, S, Neiman, DC, Beaven, S, French, SW

Publikováno v: Lu, NT; Crespi, CM; Liu, NM; Vu, JQ; Ahmadieh, Y; Wu, S; et al.(2016). A Phase i Dose Escalation Study Demonstrates Quercetin Safety and Explores Potential for Bioflavonoid Antivirals in Patients with Chronic Hepatitis C. Phytotherapy Research, 30(1), 160-168. doi: 10.1002/ptr.5518. UCLA: Retrieved from: http://www.escholarship.org/uc/item/6pf0n5w4

© 2015 John Wiley & Sons, Ltd. The hepatitis C virus (HCV) infects more than 180 million people worldwide, with long-term consequences including liver failure and hepatocellular carcinoma. Quercetin bioflavonoids can decrease HCV production in tissu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::a553b5762f02b544b4fbbd43154f9d99
http://www.escholarship.org/uc/item/6pf0n5w4

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.